Iterum Therapeutics plc

NasdaqCM ITRM

Iterum Therapeutics plc Return on Assets (ROA) for the year ending December 31, 2023: -146.13%

Iterum Therapeutics plc Return on Assets (ROA) is -146.13% for the year ending December 31, 2023, a -119.79% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Iterum Therapeutics plc Return on Assets (ROA) for the year ending December 31, 2022 was -66.49%, a 33.55% change year over year.
Iterum Therapeutics plc Return on Assets (ROA) for the year ending December 31, 2021 was -100.06%, a 36.91% change year over year.
Iterum Therapeutics plc Return on Assets (ROA) for the year ending December 31, 2020 was -158.59%, a 60.40% change year over year.
Iterum Therapeutics plc Return on Assets (ROA) for the year ending December 31, 2019 was -400.49%, a -408.67% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

NasdaqCM: ITRM

Iterum Therapeutics plc

CEO	Mr. Corey N. Fishman
IPO Date	May 25, 2018
Location	Ireland
Headquarters	Fitzwilliam Court
Employees	14
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cleaning Supplies Clinical Trials Drugstores & Retail Pharmacies Personal Care Plastics Vaccines

Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years